Screener
AbbVie ABBV Contingent consideration fair value adjustments
Contingent consideration fair value adjustments at other companies
Other financials
Where this comes from
Reported directly by AbbVie in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.
The source filing: AbbVie’s 10-Q, filed May 8, 2026.
- Filed
- May 8, 2026, 12:28 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001551152-26-000017
| (in millions) (brackets denote cash outflows) | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Depreciation | 188 | 181 |
| Amortization of intangible assets | 1,748 | 1,858 |
| Deferred income taxes | 137 | (28) |
| Change in fair value of contingent consideration liabilities | 2,387 | 1,518 |
| Payments of contingent consideration liabilities | (722) | (549) |
| Stock-based compensation | 444 | 410 |
| Acquired IPR&D and milestones | 744 | 248 |
| Non-cash litigation reserve adjustments, net of cash payments | 150 | (729) |
ITEM 1. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is AbbVie's contingent consideration fair value adjustments?
- AbbVie (ABBV) reported contingent consideration fair value adjustments of $2.39B in Q1 2026.
- How has AbbVie's contingent consideration fair value adjustments changed year-over-year?
- AbbVie's contingent consideration fair value adjustments increased by 57.2% year-over-year, from $1.52B to $2.39B.
- What is the long-term trend for AbbVie's contingent consideration fair value adjustments?
- Over 4 years (2021 to 2025), AbbVie's contingent consideration fair value adjustments has grown at a 24.8% compound annual growth rate (CAGR), from $2.68B to $6.5B.
Ask your AI about AbbVie's contingent consideration fair value adjustments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude